Literature DB >> 15833841

RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential.

Candice Elam1, Luke Hesson, Michele D Vos, Kristin Eckfeld, Chad A Ellis, Aaron Bell, Dietmar Krex, Michael J Birrer, Farida Latif, Geoffrey J Clark.   

Abstract

Ras proteins are members of a superfamily of related small GTPases. Some members, such as Ras, are oncogenic. However, other members seem to serve as tumor suppressors, such as Rig and Noey2. We now identify and characterize a novel member of the Ras superfamily, RRP22. Like Ras, RRP22 can be posttranslationally modified by farnesyl. Unlike Ras, RRP22 inhibits cell growth and promotes caspase-independent cell death. Examination of human tumor cells shows that RRP22 is frequently down-regulated due to promoter methylation. Moreover, reexpression of RRP22 in an RRP22-negative neural tumor cell line impairs its growth in soft agar. Unusually for a Ras-related protein, RRP22 localizes to the nucleolus in a GTP-dependent manner, suggesting a novel mechanism of action. Thus, we identify a new member of the Ras superfamily that can serve as a potential tumor suppressor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15833841     DOI: 10.1158/0008-5472.CAN-04-0749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Inhibition of Ras for cancer treatment: the search continues.

Authors:  Antonio T Baines; Dapeng Xu; Channing J Der
Journal:  Future Med Chem       Date:  2011-10       Impact factor: 3.808

2.  Protein transfer into human cells by VSV-G-induced nanovesicles.

Authors:  Philippe-Emmanuel Mangeot; Sandra Dollet; Mathilde Girard; Claire Ciancia; Stéphane Joly; Marc Peschanski; Vincent Lotteau
Journal:  Mol Ther       Date:  2011-07-12       Impact factor: 11.454

3.  Developmentally controlled farnesylation modulates AtNAP1;1 function in cell proliferation and cell expansion during Arabidopsis leaf development.

Authors:  Arnaud Galichet; Wilhelm Gruissem
Journal:  Plant Physiol       Date:  2006-10-13       Impact factor: 8.340

4.  RRP22: a novel neural tumor suppressor for astrocytoma.

Authors:  Ruokun Chen; Liang Yang; Jiasheng Fang; Lei Huo; Mingyu Zhang; Fenghua Chen; Jinfang Liu; Jun Wu; Yanjin Wang
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

5.  Targeting protein prenylation for cancer therapy.

Authors:  Norbert Berndt; Andrew D Hamilton; Saïd M Sebti
Journal:  Nat Rev Cancer       Date:  2011-10-24       Impact factor: 60.716

6.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Sara Ladu; Alexis Gorden; Miriam Farina; Ju-Seog Lee; Elizabeth A Conner; Insa Schroeder; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  Identification and functional analysis of NOL7 nuclear and nucleolar localization signals.

Authors:  Guolin Zhou; Colleen L Doçi; Mark W Lingen
Journal:  BMC Cell Biol       Date:  2010-09-27       Impact factor: 4.241

8.  Transcriptional repression mediated by 45-kDa calcium oxalate monohydrate binding protein.

Authors:  Coothan Kandaswamy Veena; Devarajan Asokan; Periandavan Kalaiselvi; Palaninathan Varalakshmi
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

9.  Tipifarnib in the treatment of acute myeloid leukemia.

Authors:  Xavier Thomas; Mohamed Elhamri
Journal:  Biologics       Date:  2007-12

10.  Analysis of k-ras nuclear expression in fibroblasts and mesangial cells.

Authors:  Isabel Fuentes-Calvo; Ana M Blázquez-Medela; Eugenio Santos; José M López-Novoa; Carlos Martínez-Salgado
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.